Latest market headlines for SUDARSHAN on Terminal.
30-Oct-2026 15:06:14
• Board approved proposal to issue and allot up to 72,00,00,000 warrants on preferential basis to promoters Hemal Mehta and Sachin Mehta • Each warrant convert…
29-Oct-2026 22:37:25
REVENUE UP 28.49% AT ₹216.97 CR (YOY), UP 24.40% (QOQ) EBITDA UP 117.10% AT ₹19.98 CR (YOY), UP 25.67% (QOQ) MARGINS AT 9.21% VS 5.45% (YOY), 9.12% (QOQ)
28-Oct-2026 14:29:23
REVENUE UP 47.30% AT ₹269.76 CR (YOY), UP 21.30% (QOQ) EBITDA UP 93.82% AT ₹34.48 CR (YOY), UP 34.74% (QOQ) MARGINS AT 12.78% VS 9.71% (YOY), 11.51% (QOQ)
23-Oct-2026 18:25:48
Equity shares of Re 1 each to be admitted to dealings on NSE Capital Market Segment w.e.f. October 27, 2026 after migration from BSE SME platform. Symbol SUDAR…
07-Oct-2026 14:36:24
• Proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA ("Med Therapy") has been terminated. • Proposal to acquire 1.5…
28-Sept-2026 17:39:32
• Sudarshan Pharma has completed the sale of 51% stake in its unlisted subsidiary, Ishwari Healthcare Private Limited. • The sale was made for a consideration…
15-Sept-2026 14:14:41
• Proposal to acquire 9.50% equity shares of Med Therapy Biotechnology Inc., USA is under due diligence. • Confirmation from Med Therapy Board of Directors dec…